{"filing":{"accession_number":"0001104659-26-064544","cik":"0001379006","ticker":"NNVC","company_name":"NANOVIRICIDES, INC.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"tm2615013d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465926064544/tm2615013d1_8k.htm"},"events":[{"id":9740,"run_id":8538,"accession_number":"0001104659-26-064544","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"NanoViricides entered into a Securities Purchase Agreement on May 15, 2026, for a registered direct offering of 1,133,334 shares of common stock at $1.50 per share, along with pre-funded warrants and common warrants, generating approximately $2.0 million in gross proceeds. The offering closed on May 18, 2026.","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":528,"accession_number":"0001104659-26-064544","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NanoViricides entered into a Securities Purchase Agreement on May 15, 2026, for a registered direct offering of 1,133,334 shares of common stock at $1.50 per share, pre-funded warrants, and common warrants, generating approximately $2.0 million in gross proceeds. This is a material equity issuance that dilutes existing shareholders and raises capital through the sale of registered securities, fitting the dilutive_issuance classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:43:26.317016+00:00","company_name":"","ticker":null,"filing_date":""},{"id":529,"accession_number":"0001104659-26-064544","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses an \"Offering\" announced on May 15, 2026 and closed on May 18, 2026, with press releases attached as exhibits. While the specific terms are not detailed in this Item 8.01 excerpt, the structure and timing of dual announcements (announcement and closing) is consistent with a securities offering. For a small-cap company like Nanoviricides, an offering disclosed via 8-K Item 8.01 typically represents a dilutive equity issuance or capital raise that would be material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:43:26.317016+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":528,"accession_number":"0001104659-26-064544","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NanoViricides entered into a Securities Purchase Agreement on May 15, 2026, for a registered direct offering of 1,133,334 shares of common stock at $1.50 per share, pre-funded warrants, and common warrants, generating approximately $2.0 million in gross proceeds. This is a material equity issuance that dilutes existing shareholders and raises capital through the sale of registered securities, fitting the dilutive_issuance classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:43:26.317016+00:00","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-05-20"},{"id":529,"accession_number":"0001104659-26-064544","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses an \"Offering\" announced on May 15, 2026 and closed on May 18, 2026, with press releases attached as exhibits. While the specific terms are not detailed in this Item 8.01 excerpt, the structure and timing of dual announcements (announcement and closing) is consistent with a securities offering. For a small-cap company like Nanoviricides, an offering disclosed via 8-K Item 8.01 typically represents a dilutive equity issuance or capital raise that would be material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:43:26.317016+00:00","company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","filing_date":"2026-05-20"}]}